IGF-1 LR3

A search for IGF-1 LR3-specific human trials found none — every safety and efficacy claim circulating for this compound (including the widely-repeated hypoglycemia warning) is extrapolated from IGF-1's general biology and structural similarity to insulin, not from a direct clinical study of the LR3 analog itself. This is worth stating as plainly as it was found: the actual frequency, severity, and character of adverse effects in humans specifically from IGF-1 LR3 are unknown.

IGF-1 LR3 is a modified analog of insulin-like growth factor 1, engineered (via an amino-acid substitution and extension) to bind less to IGF-binding proteins, extending its circulating half-life relative to native IGF-1. No human trial specific to this analog was found supporting any benefit claim — everything published is either general IGF-1 biology or animal/in-vitro work.

No clinically-derived dose exists for this compound. Community-use conventions weren't independently verified against any primary source.

Hypoglycemia is the primary theoretical concern, based on IGF-1's structural overlap with insulin and its activation of overlapping glucose-uptake signaling (PI3K/Akt-mediated GLUT4 translocation) — a real mechanistic basis, but not a finding from a direct human study of this specific analog. IGF-1 LR3's extended circulating half-life (reported 20-30 hours) is specifically flagged as a reason hypoglycemia risk could recur multiple times across a day if dosed without adequate food intake — again, a mechanism-based inference, not an observed clinical finding.